SAN DIEGO and BASEL, Switzerland, April 09, 2024 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing multifunctional immunotherapies for cancer and autoimmune disease,...
Bright Peak Presents New Data at AACR: BPT567Â A First-in-Class Multifunctional PD1-IL18 Immunocytokine
SAN DIEGO and BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a privately held biotechnology company developing next-generation, multifunctional precision immunotherapies for cancer and autoimmune disease, today announced the presentation of multiple new cancer immunotherapy agents at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held on November 9-12, 2022, in Boston, MA.
SAN DIEGO and BASEL, Switzerland, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a privately held biotechnology company developing next-generation multifunctional precision immunotherapies, today announced the presentation of two posters showcasing the potential of its unique chemical protein engineering platform at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments taking place October 20-25, 2022, in Chania, Crete.
SAN DIEGO and BASEL, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation precision immunotherapies to treat cancer and autoimmune disease, today announced the appointment of Jon Wigginton, M.D., as its President of Research and Development.
Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO and BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and...
SAN DIEGO and BASEL, Switzerland, Nov. 16, 2021 (GLOBE NEWSWIRE) -- nBright Peak Therapeutics, Inc., a biotechnology company developing nnext-generation cytokine immunotherapies, today announced that it has nentered into a license agreement with Livzon Mabpharm, Inc. (“Livzon”), ansubsidiary company of Livzon Pharmaceutical Group, to use LZM009, nLivzon’s proprietary anti-PD-1 monoclonal antibody currently in nlate-stage clinical trials, to develop novel PD-1 targeted nimmunocytokines (“PD-1 ICs”). The PD-1 ICs will be comprised of noptimized cytokine payloads developed by Bright Peak conjugated to nLZM009 for the treatment of a variety of cancers. PD-1 ICs are designed nto selectively target and activate cytotoxic CD8+ T cells (“CTLs”) that nexpress the inhibitory immune checkpoint PD-1 while avoiding the broad nactivation of other immune cells. Dual targeting of two receptors on thensame CTL with a PD-1 inhibitor and a cytokine payload (cis-signaling) noffers the added potential for synergistic efficacy.
Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it raised $107 million in a Series B financing. The round was led by RA Capital, with participation by founding investor Versant Ventures and new investors Fidelity Management & Research Company, Invus, Qatar Investment Authority, funds and accounts managed by BlackRock, Alexandria Venture Investments and an undisclosed leading healthcare investment fund.